Antidepressant use and risk for preeclampsia

Epidemiology

Volumn 24, Issue 5, 2013, Pages 682-691

  Palmsten, Kristin ^a   Huybrechts, Krista F ^b   Michels, Karin B ^a,b,c   Williams, Paige L ^a   Mogun, Helen ^b   Setoguchi, Soko ^a,d   Hernández Díaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; ARTICLE; COHORT ANALYSIS; DELIVERY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDICATION; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MONOTHERAPY; PREECLAMPSIA; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PUERPERAL DEPRESSION; RISK ASSESSMENT; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DATABASES, FACTUAL; DEPRESSION; FEMALE; HUMANS; MEDICAID; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84881552272     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31829e0aaa     Document Type: Article

References (48)

1. Roberts JM, Pearson G, Cutler J, Lindheimer M; NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension. 2003;41:437-445
2. Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol. 2006;195:1557-1563
3. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández- Dìaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry. 2009;166:320-328
4. Reis M, Källèn B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med. 2010;40:1723-1733
5. Palmsten K, Setoguchi S, Margulis AV, Patrick AR, Hernández- Dìaz S. Elevated risk of preeclampsia in pregnant women with depression: Depression or antidepressants? Am J Epidemiol. 2012;175:988-997
6. De Vera MA, Bèrard A. Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br J Clin Pharmacol. 2012;74:362-369
7. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol. 2000;95:487-490
8. Qiu C, Sanchez SE, Lam N, Garcia P, Williams MA. Associations of depression and depressive symptoms with preeclampsia: Results from a Peruvian case-control study. BMC Womens Health. 2007;7:15
9. Qiu C, Williams MA, Calderon-Margalit R, Cripe SM, Sorensen TK. Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy. Am J Hypertens. 2009;22:397-402
10. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: A multisite study. Am J Obstet Gynecol. 2008;198:194.e1-194.e5
11. Palmsten K, Huybrechts KF, Mogun H, et al. Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: Design considerations. PLoS ONE. 2013;8:e67405. Available at: Http://www. plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0067405. Accessed 27 June 2013
12. Huybrechts KF, Palmsten K, Mogun H, et al. National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry. 2013;35:265-271
13. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Dìaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf. 2013;22:16-24
14. West SL, Richter A, Melfi CA, McNutt M, Nennstiel ME, Mauskopf JA. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol. 2000;53:823-831
15. AC OG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159-167
16. Fox MP, Lash TL, Greenland S. A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol. 2005;34:1370-1376
17. O'Donnell JM, Shelton RC. Chapter 15. Drug therapy of depression and anxiety disorders. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011
18. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154: 854-864
19. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2011; 8 November 2011 [Epub ahead of print
20. Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41:514-520
21. Walker AM. Observation and Inference. Newton, MA: Epidemiology Resources Inc; 1991
22. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291-303
23. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-Dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173:1404-1413
24. Rassen JA, Doherty M, Huang W, Schneeweiss S. Pharmacoepidemiology Toolbox. Available at: Http://www.hdpharmacoepi.org. Accessed 25 November 2012
25. Thase ME. Effects of venlafaxine on blood pressure: A meta-Analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502-508
26. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25: 132-140
27. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: Systematic review of controlled studies. BMJ. 2005;330:565
28. Sanchez SE, Qiu C, Williams MA, Lam N, Sorensen TK. Headaches and migraines are associated with an increased risk of preeclampsia in Peruvian women. Am J Hypertens. 2008;21:360-364
29. Chen HM, Chen SF, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes for women with migraines: A nationwide populationbased study. Cephalalgia. 2010;30:433-438
30. Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal comorbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol. 2011;25:116-123
31. Hennessy S, Freeman CP, Cunningham F. Chapter 14. US government claims databases. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. 5th ed. Chichester, West Sussex, UK: Wiley-Blackwell; 2012:209-223
32. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003;158:915-920
33. Andersen J, Kristensen AS, Bang-Andersen B, Stromgaard K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb). 2009:3677-3692
34. Bjøro K, Stray-Pedersen S. In vitro perfusion studies on human umbilical arteries. I. Vasoactive effects of serotonin, PGF2 alpha and PGE2. Acta Obstet Gynecol Scand. 1986;65:351-355
35. Gonzalez C, Cruz MA, Sepulveda WH, Rudolph MI. Effects of serotonin on vascular tone of isolated human placental chorionic veins. Gynecol Obstet Invest. 1990;29:88-91
36. González C, Cruz MA, Gallardo V, Albornoz J, Bravo I. Serotonininduced vasoconstriction in human placental chorionic veins: Interaction with prostaglandin F2 alpha. Gynecol Obstet Invest. 1993;35:86-90
37. Jovanović A, Grbović L, Jovanović S. Effect of the vascular endothelium on noradrenaline-induced contractions in non-pregnant and pregnant guinea-pig uterine arteries. Br J Pharmacol. 1995;114:805-815
38. Steele SC, Warren AY, Johnson IR. Effect of the vascular endothelium on norepinephrine-induced contractions in uterine radial arteries from the nonpregnant and pregnant human uterus. Am J Obstet Gynecol. 1993;168:1623-1628
39. Yousif MH, Chandrasekhar B, Kadavil EA, Oriowo MA. Noradrenalineinduced vasoconstriction in the uterine vascular bed of pregnant rats chronically treated with L-NA ME: Role of prostanoids. J Cardiovasc Pharmacol. 2003;42:428-435
40. Ananth CV, Vintzileos AM. Medically indicated preterm birth: Recognizing the importance of the problem. Clin Perinatol. 2008;35:53-67, viii
41. Rurak D, Lim K, Sanders A, Brain U, Riggs W, Oberlander TF. Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatr Res. 2011;70:96-101
42. Monk C, Newport DJ, Korotkin JH, Long Q, Knight B, Stowe ZN. Uterine blood flow in a psychiatric population: Impact of maternal depression, anxiety, and psychotropic medication. Biol Psychiatry. 2012;72: 483-490
43. Patten SB, Esposito E, Carter B. Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiol Drug Saf. 2007;16:746-752
44. Smitherman TA, Walters AB, Maizels M, Penzien DB. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011;17: 462-469
45. Bodnar LM, Ness RB, Markovic N, Roberts JM. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol. 2005;15:475-482
46. Conde-Agudelo A, Althabe F, Belizán JM, Kafury-Goeta AC . Cigarette smoking during pregnancy and risk of preeclampsia: A systematic review. Am J Obstet Gynecol. 1999;181:1026-1035
47. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden-Assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol. 2011;3:43-50
48. Garcia G. Maternal and Child Health (MCH) Update: States Increase Eligibility for Children's Health in 2007. Available at: Http://www.nga.org/ files/live/sites/NGA /files/pdf/0811MCHUPDATE .PDF;jsessionid=7B47 A647247DD4E5CB9B709C8F9797AE. Accessed 25 November 2012